MANY LUNG DISEASES ARE CHARACTERIZED by the infiltration of inflammatory and immune cells in the airways and the lung tissues (32, 100, 119) . Although the inflammatory and immune cell trafficking to the site of injury or inflammation represents an integral and beneficial part of the normal host defense, excessive and prolonged inflammatory and immune responses may lead to tissue damage and development of pathological conditions (8, 127, 166) .
Chemokines, a large group of chemotactic cytokines, and their receptors have been identified as key mediators of inflammatory/immune cell trafficking (113, 121, 152) . The interaction between chemokines and their specific receptors leads to activation of intracellular signaling and subsequent chemotactic migration of the targeted cells, which then contribute to the restoration of tissue structure, function, and homeostasis (80, 143) . Chemokine receptors and their ligands are involved in the protection of the lung against external damaging agents (31, 145, 162, 163) . However, in case of breakdown of the protecting barrier and loss of inflammatory and immune controls, they have been identified as key players in the development of inflammatory lung diseases (40, 119, 134, 158) . Therefore, they represent attractive therapeutic targets for the treatment of inflammatory lung disorders. The finding that expression of chemokine receptors/chemokines is not only limited to inflammatory and immune cells, but also to the structural lung cells, attributes them a more significant role in the regulation of homeostasis in the lung. The chemokine receptors and their ligands, expressed by both inflammatory/ immune and resident structural lung cells, act in a coordinated way and orchestrate the complex signaling network leading to restoration of normal lung functions.
In this article, after brief overview of the chemokine receptor-chemokine system, we summarized current knowledge on the implication of chemokine receptors in chronic obstructive pulmonary disease (COPD), asthma/allergic airway disease, pulmonary fibrosis, acute lung injury (ALI), and lung infection. We then discussed the potential use of chemokine receptors as therapeutic targets, and the contribution of chemokine receptors expressed in structural lung cells to the repair and regeneration of the lung tissues. Furthermore, we delineated the role of chemokine receptors in the interplay between structural lung cells and inflammatory and immune cells recruited to the lung in response to injurious stimuli, which is crucial for maintaining/restoring normal lung function. nated G protein-coupled receptors (GPCRs) (93) . The family of chemokine receptors consists of 18 members divided into several classes according to their ligands, chemokines, which are classified based on the spatial arrangement of cysteine residues in their amino terminus: 10 CC chemokine receptors (CCR1-10), 6 CXC chemokine receptors (CXCR1-6), 1 CX3C chemokine receptor (CX3CR1), and 1 C chemokine receptor (XCR1) (177) . Furthermore, six atypical (nonchemotactic, recycling, or scavenging) chemokine receptors (ACKR1-6) have been described (7) .
Chemokine receptors exert their biological functions through binding to chemokines, a superfamily of about 50 chemotactic cytokines (102, 177) . The binding of ligands to extracellular domains of chemokine receptors induces the conformational changes of these GPCRs, facilitating their interactions with intracellular heterotrimeric G proteins and a GDPto-GTP exchange (131) . This leads to the dissociation of the GTP-bound G␣ subunit from the G␤␥ heterodimers, allowing both subunits to trigger downstream signal transduction pathways, including JAK/STAT, FAK, MAPK, and PI3K pathways (128, 168) . Table 1 shows that the interactions between chemokine receptors and their ligand(s) are highly variable, in terms of selectivity (some chemokines bind only one receptor and vice versa) and redundancy (some chemokines bind more than one receptor, and many receptors recognize more than one chemokine) (85, 102) . Besides their crucial role in leukocyte chemoattraction (113) , chemokine receptors and their ligands have been implicated in a number of biological functions, including regulation of hematopoiesis and organ development, fibrosis, angiogenesis, and tumor growth (45, 85, 132) . Excessive expression and activation of these molecules may lead to sustained inflammation and influx of inflammatory and immune cells into affected tissue, resulting in the development of diverse pathological conditions (166) .
CHEMOKINE RECEPTORS AND THEIR IMPLICATION IN LUNG DISEASES
Chemokine receptors and their ligands have been implicated in the pathogenesis of chronic lung diseases such as COPD (27, 30, 40) , asthma/allergic airway diseases (92, 95, 120) , and pulmonary fibrosis (75, 150, 151) . Moreover, there is evidence on the implication of chemokine receptors/chemokines in ALI (18) and lung infection (117, 144) . To determine the role of chemokine receptors, mice with a particular gene knockout have been used in different lung disease models (Table 2 ). In addition, antibodies and specific inhibitors of chemokine receptors have been used; some of them appear as attractive therapeutic targets (Table 3 ). The chemokine receptors being studied for each major lung disease are summarized in Fig. 1 . CCR4  CCL3/MIP-1␣, CCL5/RANTES, CCL17/TARC, CCL22/MDC  CCR5  CCL2/MCP-1, CCL3/MIP-1␣, CCL4/MIP-1␤, CCL5/RANTES, CCL7/MCP-3, CCL8/MCP-2, CCL11/eotaxin,  CCL13/MCP-4, CCL14/HCC-1, CCL16/HCC-4, CCL3L1, CCL3L3  CCR6  CCL20/MIP-3␣  CCR7  CCL19/ELC, CCL21/SLC  CCR8  CCL1/I-309, CCL4/MIP-1␤, CCL16/HCC-4, CCL17/TARC  CCR9  CCL25/TECK  CCR10  CCL2/ 
Chemokine Receptors in Chronic Lung Diseases
Chemokine receptors in COPD. COPD is a common respiratory disorder characterized by progressive airflow obstruction of the peripheral airways, which results from the interaction of genetic and environmental factors such as cigarette smoke (CS) (47) . The environmental/occupational exposure to organic or inorganic particles also represents a significant risk (47) . An important feature of COPD is the ongoing chronic inflammatory process in the airways mediated mainly by neu- trophils; recruitment and activation of macrophages and T lymphocytes are also underlying mechanisms of COPD (53) . The majority of studies investigating the role of chemokine receptors in COPD are based on animals exposed to CS. Of CC chemokine receptors, CCR5 and CCR6 have been proposed to be involved in the development of COPD (21) . Mice deficient in CCR5 or CCR6 showed attenuated accumulation of inflammatory cells, including macrophages, dendritic cells, neutrophils, and CD8 ϩ T lymphocytes, upon CS exposure; moreover, CCR5-or CCR6-deficient mice were partially protected against pulmonary emphysema (21, 22) . CCR5 antibody blockade or CCR5 deficiency in a murine emphysema model resulted in decreased inflammation, DNA damage, apoptosis, and alveolar remodeling (98) . The CCR6 has only a single known chemokine ligand, CCL20/macrophage inflammatory protein (MIP)-3␣ (Table 1) , even though it has been reported to be able to interact with ␤-defensins (172). The CCR6-CCL20 axis may thus represent a potential target for therapeutic intervention.
Among the CXC receptor family, CXCR1/CXCR2 and CXCR3 are involved in the pathogenesis of COPD. In a rat model of COPD, the CXCR2 antagonist SB-332235 effectively inhibited CS-induced neutrophilia (148) . In mice exposed to CS, another orally active small molecule inhibitor of CXCR2, SCH-N, also reduced neutrophilic inflammation and associated lung tissue damage (157) . A study by Chapman et al. (28) evaluated a potent and selective CXCR1/CXCR2 antagonist, SCH-527123, in murine, rat, and primate models of pulmonary inflammation, each model recapitulating particular critical features of inflammation: mice/rats were challenged with lipopolysaccharide (LPS), rats were challenged with vanadium pentoxide, and cynomolgus monkeys were undergoing repeated bronchoscopy and lung lavage. A CXCR1/CXCR2 antagonist significantly attenuated neutrophil recruitment and inhibited goblet cell hyperplasia and mucus production (28) . Deficiency in CXCR3 showed significant reduction in the severity of lung inflammation in mice after exposure to CS (115).
Therefore, chemokine receptor antagonism represents an attractive approach to COPD therapy (30, 40) . It should be pointed out that most of these COPD studies used CS as the model system, which does not fully recapitulate the pathological conditions of the disease (10) . Furthermore, there is no information on the potential role of chemokine receptors and their ligands in tissue repair processes after damage by tissuedegrading enzymes that are released by neutrophils and macrophages (53) . The lack of proper large animal models for COPD is also the obstacle of translating knowledge from small animal studies to clinical studies.
Chemokine receptors in asthma/allergic airway diseases. Asthma is a complex genetic disorder affected by a number of environmental stimuli (24) . Although the adaptive immunity and Th2 cells have been considered as crucial components in the pathogenesis of asthma, it is becoming clear that innate immune mechanisms also significantly contribute to the pathogenesis of asthma. The mechanisms, including both allergic pathways (adaptive immunity) and nonallergic (innate) pathways, are implicated in asthma and contribute to the complexity of this disease (77) . Therefore, the development of relevant models to study the mechanisms leading to the development of asthma is a great challenge (26, 69) . Current models mainly use allergic airway disease as an alternative for asthma, and many models are based on short-term, acute exposures to simple protein antigens, microorganisms, or chemical compounds (5) .
In terms of CC chemokine receptors, the CCR2, CCR3, CCR4, CCR5, and CCR6 have been implicated in asthma and allergic airway diseases. The role of CCR2 has been extensively studied in asthma/allergic airway diseases with controversial results. When challenged with ovalbumin (OVA), CCR2-deficient mice were characterized by increased hyperreactivity and enhanced airway inflammation (78, 99) . Similarly, Aspergillus fumigatus challenge induced enhanced airway inflammation, hyperresponsiveness, and subepithelial fibrosis in CCR2-deficient mice; moreover, CCR2-deficient mice were more susceptible to the injurious effects of an intrapulmonary challenge with live A. fumigatus conidia (19). Mice deficient in CCR2 or its ligand, CCL2/monocyte chemoattractant protein (MCP)-1, developed eosinophilic airway inflammation, goblet cell hyperplasia, airway hyperreactivity, and airway fibrosis in response to Aspergillus antigen challenge (82) . Thus, results from these experimental models suggest that CCR2 may have inhibitory effects on the inflammation caused by sensitization with these allergens. On the other hand, using a murine model of cockroach antigeninduced allergic airway inflammation, the antibody of CCL2/ MCP-1 inhibited changes in airway resistance and attenuated histamine release into the bronchoalveolar lavage (BAL) (25) . In addition, allergen-induced as well as direct CCL2/MCP-1-induced changes in airway hyperreactivity were significantly attenuated in CCR2-deficient mice (25) . The blockade of CCR2 by specific antibody led to reduced bronchial hyperresponsiveness and attenuated macrophage and eosinophil accumulations in BAL of a primate model challenged with Ascaris suum (106) . These controversial findings regarding the role of CCR2 in asthma/allergic airway diseases may be the result of different allergens used to sensitize the animals, suggesting that, clinically, CCR2 inhibition/stimulation should be considered based on allergens identified. In addition, because CCR2 interacts with numerous ligands (Table 1) , some of them also binding other chemokine receptors such as CCR3 and CCR5, there may be certain "substitution" between receptors when interacting with their ligands. The complexity of chemokines and their receptors is the major challenge for our understanding of their roles in asthma/allergic airway diseases.
The CCR3-deficient mice, when immunized and challenged with OVA, showed significant reduction in eosinophil recruitment to the lung (62). Similar results have been shown when using antibody of CCR3 in OVA-sensitized mice (72) . Interestingly, although several ligands can bind both CCR2 and CCR3, some ligands are CCR2 specific (such as CCL2/MCP-1) and some are CCR3 specific (such as CCL11/eotaxin, CCL24/eotaxin-2, CCL26/eotaxin-3) ( Table 1 ). This specificity may be important for the search of therapeutic targets. Attenuation of airway hyperresponsiveness, but not airway remodeling, was observed in mice deficient in CCR4 after A. fumigatus antigen-induced chronic pulmonary allergic responses (139) . Blockade of CCR5 by a small synthetic compound, TAK-779, reduced airway hyperreactivity in OVA-sensitized mice (154) . The CCR6 deficiency in mice challenged with cockroach antigen caused reduction of eosinophil recruitment and airway hyperreactivity (96) . Taken together, multiple CCRs can be activated depending on the allergens, which affect the development of these receptors as targets for therapeutic intervention.
CXC chemokine receptors also play roles in asthma and allergic airway diseases. Mice deficient in CXCR2, when challenged with A. fumigatus (138) or ozone (68), were characterized by significant attenuation of airway remodeling. Two selective CXCR2 antagonists, SCH-527123 (61) or SB-656933 (84), caused significant attenuation of ozone-induced airway neutrophilia in healthy subjects. Treatment with AZD-8309, a potent small molecule reversible CXCR2 antagonist, led to reduction of inflammation and airway neutrophilia in healthy volunteers challenged with LPS, an inducer of acute neutrophilic response in the airways (86, 164) . In patients with severe asthma, treatment with another selective CXCR2 antagonist, SCH-527123, resulted in reduction of sputum neutrophils accompanied by moderate improvement in asthma features (114) .
Mice deficient in CXCR3 showed significant reduction in the severity of allergic airway hyperresponsiveness and inflammation (88) . Blockade of CXCR3 by a small synthetic compound, TAK-779 (also blocking CCR5), reduced airway hyperreactivity and prevented asthma features in OVA-sensitized mice (154) . Neutralization of CXCR4 and its ligand, CXCL12/ stromal cell-derived factor (SDF)-1␣, with specific antibodies reduced lung eosinophilia accompanied by a significant decrease in airway hyperresponsiveness in OVA-sensitized mice, whereas overexpression of CXCR4 resulted in greater inflammation (51) . Treatment of cockroach antigen-sensitized mice with AMD-3100, a specific soluble inhibitor of CXCR4, significantly reduced airway hyperreactivity, peribronchial eosinophilia, and overall inflammatory responses (94) . Moreover, treatment with carbonitrile-chalcone 4, a drug that blocks binding of CXCL12 to CXCR4, resulted in the anti-inflammatory effect in OVA-sensitized mice (36) . These results indicate that blocking CXCR2 and CXCR3 may attenuate airway inflammation mediated by neutrophils, whereas CXCR4 seems to be involved in eosinophilia seen in allergic responses. The interaction between CXCR4 and its single ligand (CXCL12/ SDF-1␣) could be a good target for therapeutic intervention.
To determine the molecular mechanisms of asthma and allergic airway disease, most of the studies used a single allergen. To develop effective therapeutics, more sophisticated animal models (39) recapitulating the complexity of clinical asthma and allergic airway diseases are needed. Because both CCRs and CXCRs are involved in asthma and allergic airway disease, the combination of CXCR and CCR blockade should be considered, where CXCRs mainly mediate recruitment and activation of neutrophils and monocytes, whereas CCRs mainly mediate functions of lymphocytes, eosinophils, and mast cells.
Chemokine receptors in pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is the fatal form of interstitial lung diseases, a group of heterogeneous disorders, either idiopathic or associated with injurious or inflammatory causes (104) . The current understanding assumes that IPF is a result of multiple injuries at different sites of the lung followed by aberrant repair, which can gradually evolve into a pathogenic fibrotic response (104) . In addition, recent studies have shown that autoimmune response is also a possible pathogenic pathway for IPF (43, 103) . Although most animal studies on the role of chemokine receptors are based on exposure of bleomycin (BLM) (109), other models using fluorescein isothiocyanate (FITC), silica, or irradiation have been also introduced (38) .
Among CCRs, CCR2 and CCR4 have been implicated in pulmonary fibrosis. In both FITC and BLM-induced pulmonary fibrosis models, mice deficient in CCR2 were protected with less fibrotic lesions (111) . Moreover, overexpression of the mutant gene for CCL2/MCP-1, a ligand for CCR2, which acts as a specific and dominant negative inhibitor of wild-type CCL2/MCP-1, resulted in consistent reduction in the degree of BLM-induced fibrosis, particularly in later stages of the disease (64) . CNTO 888, a monoclonal antibody against CCR2 ligand, CCL2, has been investigated in a double-blind, placebo-controlled phase II trial in IPF patients (NCT00786201); the study has been completed, and the results are awaited. Patients with IPF have a significantly higher CCR4 expression on CD4ϩ T cells in BAL (126) . In addition, in BLM-treated CCR4-deficient mice, macrophages showed an M2 phenotype favoring the attenuation of inflammation and tissue injury (159) . Neutralization of CCL17, a ligand for CCR4, significantly reduced BLM-induced pulmonary fibrosis (12) . Blocking CCR2 and/or CCR4 are promising therapeutic interventions in pulmonary fibrosis.
Activation of CXCR2 and CXCR4 appears to be involved in the pathogenesis of pulmonary fibrosis. The neutralizing antibody of CXCL2/MIP-2 reduced significantly the fibrotic response in BLM-instilled mice (74) . Moreover, administration with a long-acting orally bioavailable CXCR2 antagonist, DF-2162, led to an improvement of the lung pathology and reduced collagen deposition in BLM-treated mice (133) . In a mouse model of bronchiolitis obliterans syndrome (BOS), a fibrotic process in the small airways and lung parenchyma seen after bone marrow or lung transplantation (35) , the treatment with anti-CXCR2 antibody inhibited early neutrophil infiltration and later vascular remodeling, resulting in the attenuation of BOS (11) . In mice treated with BLM, the administration of TN-14003 (170) or AMD-3100 (146), which are specific CXCR4 antagonists, significantly attenuated lung fibrosis, probably because of the modification of Th2/Th1-type response (75) . Moreover, BLM-instilled mice, when treated with CXCR4 antagonist, AMD-3100, showed significant improvement in the loss of body weight and reduced collagen content and fibrotic score in the lung (101) . In addition, treatment with neutralizing CXCL12/SDF-1␣ antibody attenuated BLM-induced pulmonary fibrosis in mice (124) .
Interestingly, the role of CXCR3 in IPF seems to be opposite with CXCR2 and CXCR4. First, patients with IPF had a significantly lower CXCR3 expression on CD4ϩ T cells in BAL, and patients treated with corticosteroids exhibited higher CXCR3 (126) . The CXCR3 deficiency in mice resulted in increased mortality and progressive interstitial fibrosis when exposed to BLM (66) . Moreover, mice deficient in CXCL10, a CXCR3 ligand, exhibited increased pulmonary fibrosis after BLM administration, whereas transgenic mice overexpressing CXCL10 exhibited decreased fibrosis and mortality after BLM exposure (155) . Treatment with CXCL11, one of the ligands of CXCR3, resulted in amelioration of fibrosis in the lung of BLM-treated mice (23) . Taken together, these findings suggest that CXCR3 receptor and its ligands are protective against fibrotic processes.
In summary, animal studies in mainly BLM-induced fibrosis nominated CCR2 and CCR4 together with CXCR2 and CXCR4 as promising therapeutic targets for IPF. On the other hand, activation of CXCR3 with its ligands may be of particular interest for future research and potential therapeutic intervention in IPF.
Chemokine Receptors in Lung Injury
ALI or its severe form acute respiratory distress syndrome (ARDS) is an inflammatory injury to the alveolocapillary membrane (105) . There is extensive experimental evidence demonstrating the critical role of inflammatory cells, including neutrophils and mononuclear cells, and inflammatory mediators, such as chemokines and their receptors, in the pathogenesis of ALI (2, 108, 174) . ALI/ARDS can be induced by multiple pathological conditions, including extrapulmonary (such as sepsis, acute pancreatitis, trauma, severe hemorrhage, etc.)-and intrapulmonary (such as ischemia-reperfusion, mechanical ventilation, hyperoxia, etc.)-related injury.
Protective effect was observed in sepsis-induced lung injury in mice when using the CCR1 antagonist BX-471 (57). Mice challenged with caerulein, when treated with CCR1 antagonists, Met-RANTES (17) or BX-471 (56), were protected from ALI associated with acute pancreatitis. The CCR1 deficiency protected mice from pulmonary inflammation secondary to acute pancreatitis (48) . Similarly, in LPS-induced ALI, the inhibition of CCR3 by its specific inhibitor SB-328437 led to the improvement of ALI condition in mice (87) . These results suggest that CCR1 and CCR3 could be therapeutic targets for both sepsis-and acute pancreatitis-induced ALI. Probably, blocking these receptors may protect the lung from acute injury induced by other causes.
In rat and murine models, CXCR2 antibody resulted in attenuation of ischemia-reperfusion-induced lung injury (13) , as well as ventilator-induced lung injury (14). In addition, mice treated with CXCR2 antagonists, antileukinate (16) or Reparixin (173), were protected from ALI. In a mouse model of hyperoxia, CXCR2 deficiency caused significant attenuation of lung injury and prolonged survival (153) . The deficiency in CXCR3 attenuated caerulein/arginine-induced lung edema and inflammatory cell infiltrate in the lung tissue and thus attenuated acute pancreatitis-associated lung injury (142) . Thus, inhibition of CXCR2 and CXCR3 may represent a useful therapeutic tool for ALI.
The deficiency in Duffy antigen/chemokine receptor (DARC), an atypical chemokine decoy receptor, resulted in elevated neutrophil migration with increased concentrations of CXCR2 ligands, CXCL1 and CXCL2/3, in the alveolar space of mice challenged with aerosolized LPS, suggesting that DARC is a critical regulator of CXCL1 and CXCL2/3 expression and has effects on the directed leukocyte trafficking to inflamed tissue (130) .
Results from these experimental studies strongly support the notion that the acute inflammatory response is one of the important underlying mechanisms of ALI, involving CC, CXC, and atypical chemokine receptors. Further studies on large animal preclinical experimental models are prerequisite for clinical applications of these therapeutics.
Chemokine Receptors in Lung Infection
Because the airways are repeatedly exposed to a multitude of airborne particles and microorganisms, an elaborate system of defense mechanisms has been developed to maintain the sterility of the lung. Besides, a dual phagocytic system involving in both alveolar macrophages and neutrophils, the recruitment and activation of inflammatory and immune cells at a site of infection, and the establishment of chemotactic gradients via the proinflammatory cytokines and chemokines are crucial for the elimination of exogenous microorganisms from the alveolar space (175) . However, the viral, bacterial, and fungal infection varies according to different species and strains of microorganisms. To summarize the role of chemokine receptors in lung infection is difficult; a limited number of reports will be presented here as examples.
When challenged with respiratory syncytial virus (RSV), CCR1-deficient mice, or wild-type mice treated with smallmolecule chemokine receptor antagonist, Met-RANTES, showed attenuated inflammation and reduced morbidity and mortality (20, 107) . By contrast, when CCR5-deficient mice were challenged with RSV, the clearance of virus infection was delayed when compared with wild-type mice (81) . Therefore, these two CCRs showed opposite effects on RSV infection. CCR2-deficient mice challenged with influenza virus showed reduction in weight loss and mortality and decrease in pulmonary inflammation and lung injury (89, 165) . Moreover, reduced morbidity and mortality in influenza-induced mice was observed after the administration of the CCR2 inhibitor PF-04178903 (90) .
By contrast, CCR2-deficient mice challenged with Cryptococcus neoformans showed impairment of cryptococcal lung clearance (118) . In CCR2-deficient mice, Mycobacterium tuberculosis induced a rapidly progressive course and inability to control the growth of M. tuberculosis in the lung (122) . Obviously, the role of this chemokine receptor depends upon the types of microorganisms infected in the lung. Mice deficient in CCR4, when challenged with M. bovis, showed reduced inflammation and delayed bacterial clearance (149) . On the other hand, the deficiency of CCR6 in mice resulted in more severe infection and higher mortality rate and lung fungal burden when challenged with A. fumigatus (123) . Again, various CCRs may play different roles in lung infection depending on the types of pathogens.
In terms of CXC receptors, CXCR2 appears to be protective in bacterial infection in the lung. CXCR2 antibody increased mortality in a mouse model of pneumonia (156) . In a mouse model of Pseudomonas aeruginosa infection, CXCR2 antibody increased mortality and decreased bacterial clearance (160) . Similarly, CXCR2 antibody in mice challenged with Nocardia asteroides increased mortality and bacterial burden (112) . When challenged with Streptococcus pneumoniae, CXCR2-deficient mice or wild-type mice treated with CXCR2 inhibitor (SB-225002) exhibited increased mortality, overgrowth of pneumococci in the lung, and perturbation of the lung host defense against pathogens (59) . CXCR2-deficient mice challenged with Yersenia pestis also developed severe pneumonia compared with wild-type mice (42) . However, when CXCR2-deficient mice were challenged with M. avium (50) and M. tuberculosis (116) , no impact on the mycobacterial growth and enhanced survival with decreased inflammation compared with wild-type mice were observed. These results suggest again that CXCR2 may play different roles in lung infection depending on the type of pathogens.
The reports on the role of other CXCRs and other chemokine receptor families in lung infection are limited. Mice with CXCR3 deficiency, when challenged with Bordetella bronchiseptica, showed delayed clearance of bacteria from the lung and the trachea (167) . In mice deficient in fractalkine receptor, CX3CR1, no impact on the ability of the host to control the RSV infection (67) and M. tuberculosis/Francisella tularensis infection (54) was observed.
The studies on chemokine receptors for most of the microorganism pathogens in the lung have just emerged. The experimental findings point out some chemokine receptors (such as CXCR2 in pneumonia) as interesting targets for the modulation of response to infection in the lung. However, most of these studies are based on mouse models, and infection of microorganisms, especially viral infection, could be species specific. Therefore, more investigations are required before drawing strong conclusions.
Chemokine Receptors as Potential Targets for the Treatment of Lung Diseases
Because the chemokine receptors/chemokines have been implicated in numerous lung diseases, they are attractive targets for therapeutic intervention. Multiple CC receptors are related to asthma and allergic airway diseases, as well as viral infection. CXCR2 activation is involved in COPD, IPF, and asthma/allergic airway diseases; blocking CXCR2 may reduce chronic inflammation and provide therapeutic benefits. On the other hand, blocking CXCR2 may accelerate acute inflammatory response and enhance ALI and pneumonia. While CXCR3 activation is also involved in the pathogenesis of COPD, asthma/ allergic airway diseases, and lung injury, it seems to be protective in IPF and beneficial for the clearance of B. bronchiseptica. CXCR4 activation is implicated in asthma/allergic airway diseases, pulmonary fibrosis, and pneumonia. Because CXCR4 only has one chemokine ligand, it may represent special opportunity to develop therapeutics. Reported potential therapeutics against chemokine receptors are also presented in Table 3 .
So far, only a limited number of chemokine receptors has been studied in lung diseases. The role of other chemokine receptors and atypical receptors in the lung diseases should also be studied. Although a number of antibodies and selective antagonists for particular chemokine receptors have been used (Table 3) , most of these studies are based on animal models. Therefore, the translation of this knowledge and potential therapeutics to clinical practice remains an immense challenge.
Having said that, CXCR2 antagonists have been tested in healthy volunteers, showing reduction of ozone-or LPS-induced airway neutrophilia (61, 84, 86) . The first clinical trial focused on safety on severe asthma patients showed moderate improvement of asthma features after blocking CXCR2 (114) . Moreover, the effect of a monoclonal antibody against CCR2 ligand, CCL2, has been investigated in IPF patients (NCT00786201). In addition, clinical trials using antagonists or antibodies for particular chemokine receptors involved in rheumatoid arthritis, multiple sclerosis, or reperfusion injury have been conducted or are ongoing (4, 79) . These studies are promising to promote further research and clinical trials targeting chemokine receptors and their ligands in lung diseases.
CHEMOKINE RECEPTORS IN THE LUNG: MORE THAN LEUKOCYTE TRAFFICKING
Because of their capability to attract inflammatory and immune cells to the site of injury or inflammation, chemokine receptors/chemokines act as key mediators of inflammatory and immune responses (135) . However, lung tissue cells, including airway/alveolar epithelial cells, airway smooth muscle (ASM) cells, and lung fibroblasts, also express chemokine receptors/chemokines. The functions of chemokines and their receptors in these structural cells are not limited to cell migration and proliferation, crucial events to repair the damaged tissue, but are also linked to other cell functions, such as mucin secretion and collagen synthesis (Table 4) . They appear to represent important molecular signals for communication between inflammatory, immune, and resident lung tissue cells, thus contributing to the processes leading to restoration of normal lung functions.
Role of Chemokine Receptors in Airway/Alveolar Epithelial Cells
The airway epithelium is in contact with the external environment, thus playing a vital role in the protection of the lung against external damaging agents (37). It has a unique capability of regeneration; a series of processes, including epithelial cell migration, followed by proliferation and differentiation of epithelial cells, is initiated to restore the epithelial barrier and normal lung function after tissue damage (37, 169) . Both CC and CXC receptors have been found expressed in airway/ alveolar epithelial cells, where they contribute mainly to cell migration and proliferation.
The interaction of a splice variant of CCR2, CCR2B, with CCL2/MCP-1 induced cell proliferation and migration of human bronchial epithelial cells (97) . LPS or IL-2 induced CCR2B expression (97) . When cells were stimulated with CCL2/MCP-1, increased mucin secretion via MAPK activation was observed (110) . Another CC receptor, CCR3, is found in the human airway epithelial cell line NCI-H292 (87) where its expression can be induced by TNF-␣ or IFN-␥ (147). Moreover, the interaction of CCR3 with its ligand CCL11/eotaxin led to tyrosine phosphorylation of cellular proteins (147) . In addition, CCL11/eotaxin together with other CCR3 ligands, CCL24/eotaxin-2 and CCL26/eotaxin-3, were able to induce proliferation and migration of airway epithelial cells (9) .
The expression of CXCR1 and CXCR2 has also been reported in human bronchial epithelial cells (44); however, their role in the airway epithelium remains to be elucidated. Another CXC chemokine receptor, CXCR3, is involved in a number of cellular processes in human bronchial epithelial cells (3, 76, 141) . The interaction of CXCR3 with its most potent ligand CXCL11/I-TAC leads to increased chemotaxis, cell proliferation, DNA synthesis, and actin reorganization (3, 76, 141) . CXCR3-induced chemotaxis is critically dependent on signaling via p38 MAPK and PI3K/Akt pathways (141) . CXCR4 expression was induced by IL-1␤ and bradykinin in primary human bronchial epithelial cells (41) . Moreover, the binding of CXCR4 to its ligand CXCL12/SDF-1␣ resulted in rapid phosphorylation and activation of ERK and SAPK/JNK (41) . However, a direct implication of CXCR4 receptor in migration of airway epithelial cells has not been demonstrated yet.
In alveolar epithelial cells, the CC and CXC receptors are involved mainly in cell migration. CCR2, expressed in murine type II alveolar epithelial cells, was implicated in cell migration in a wound-healing assay induced by CCL2/MCP-1 (33) . The expression of CCR3, which could be induced by TNF-␣, IL-1␤, IL-4, and IL-13 (1, 58) , has been reported in human alveolar basal epithelial cells (A549 cells). Moreover, A549 cells also expressed CCR5 after CCL3/MIP-1␣ stimulation (1) . However, the function of these CC receptors has not been specified yet in this cell type.
The human primary type II alveolar cells and A549 cells expressed both CXCR3 splice variants (CXCR3-A, CXCR3-B) (65) . The activation of ERK, p38, and PI3K/Akt kinases was induced by the most potent CXCR3 ligand, CXCL11/I-TAC. In addition, interaction between CXCR3 and its ligands (CXCL9/Mig, CXCL10/IP-10, and CXCL11/I-TAC) resulted in cell migration (65) . CXCR4 receptor expressed in murine/rat type II alveolar cells regulated cell migration in response to CXCR4 ligand CXCL12/SDF-1␣ via Rac1, a downstream effector of the PI3K pathway (49) . Because the primary alveolar cells have limited capacity to proliferate in vitro (63) , the modulation of alveolar epithelial cell proliferation by the chemokine receptor-chemokine system is largely unknown. However, we do suspect that this system may have promoted proliferation of alveolar epithelial cells in vivo. The knowledge on chemokine receptor expression and function in alveolar epithelial cells is based mainly on human lung cancer (A549) cells or murine/rat cells. The studies on normal or diseased human cells are required to determine the chemokine receptor function in alveolar epithelial cells.
Because migration and proliferation are crucial and fundamental steps in the tissue repair and regeneration, chemokine receptors may be important regulators of lung tissue repair after injury. Therefore, they may be interesting targets for future therapeutic strategies, which would be based on stimulation of reparatory processes in the lung, leading to repair of damaged tissue and restoration of normal lung function. Although chemokine receptors are expressed constitutively in airway/alveolar epithelial cells, their expression could be further induced by various inflammatory mediators, such as cytokines and chemokines. Therefore, the local inflammation is supposed to be a beneficial factor in lung tissue repair, promoting expression of chemokine receptors, which then contribute to cell migration/proliferation. However, excessive inflammation with the infiltration of inflammatory cells may change the balance between repair and continuous damage, suggesting the importance of control mechanisms ensuring "limited local inflammation" in favor of tissue repair.
Role of Chemokine Receptors in ASM Cells
ASM represents an important tissue involved in the regulation of bronchomotor tone (6) . Although the physiological relevance of ASM in healthy airways remains unclear, there is evidence on ASM implication in disease states such as asthma, chronic bronchitis, and emphysema (6) . Both CC and CXC chemokine receptors have also been found expressed in ASM cells, where they have been involved mainly in migration and proliferation processes. CCR1, when stimulated by its ligand CCL5, regulated ASM cell proliferation via p42/p44 MAPK activation (55) . Similarly, CCR3, when stimulated by its ligand CCL11/eotaxin, regulated ASM cell migration and proliferation via p42/p44 MAPK activation (55, 70, 136) . The CCR7-CCL19 interaction increased ASM cell migration (73) .
When stimulated by CXCL8/IL-8, CXCR1 and CXCR2 regulated migration and proliferation of human primary ASM cells (52, 55, 136) , and stimulation of CXCR1/2 by CXCL8/IL-8 led to increased human ASM cell contraction (52) . CXCR3 and CXCR4 were implicated in ASM cell migration in a wound-healing assay, when stimulated by their ligands, CXCL10/IP-10, or CXCL12/ SDF-1␣, respectively (136) .
Conversely to airway/alveolar epithelial cells, the involvement of chemokine receptors in ASM cells has been studied using human primary cells through biopsies, thus giving more reliable information on chemokine receptor functions than immortalized cell lines. Because increased proliferation of ASM cells is one of the important contributors to airway remodeling in asthma (176) , chemokine receptors in ASM cells may thus contribute to asthma pathogenesis, through induced cell proliferation. Blockade of these chemokine receptors may not only reduce immune cell infiltration into the lung but also reduce resident ASM cell proliferation, migration, and contraction, therefore, more effectively control the symptoms and development of asthma/allergic airway diseases.
Role of Chemokine Receptors in Lung Fibroblasts
Lung fibroblasts play a critical role in the homeostasis of extracellular matrix in the lung, contributing to normal wound healing. However, excessive activation of fibroblasts may also contribute to the development of interstitial lung diseases, such as IPF (91) .
Lung fibroblasts have been shown to express CC chemokine receptors, involved mainly in migration and proliferation. CCR2 expression has been reported in murine lung fibroblasts (60) . Activation of CCR3, by its ligand CCL11/eotaxin, resulted in increased migration and proliferation of human lung fibroblasts (129) . CCR5 promoted murine lung fibroblast migration when cells were stimulated by its ligand CCL4 (161) . CCR7 regulated migration and proliferation of IPF fibroblasts when stimulated by its ligand CCL21, with the activation of the ERK1/2 MAPK signaling pathway (125) . Stimulation of CCR3 with its specific ligand CCL11/eotaxin also led to increased collagen synthesis (129) .
Lung fibroblasts are required for lung tissue repair and regeneration. However, under pathological conditions, the local inflammatory response leads to excessive production of cytokines/chemokines and increased expression of chemokine receptors, which may increase proliferation and migration of lung fibroblasts and, subsequently, contribute to the development of fibrotic processes.
Interestingly, only CC receptors have been reported in lung fibroblasts. The expression of CXC receptors in lung fibroblasts and their potential function are largely unknown. A study on dermal fibroblasts has shown the involvement of CXCR4 in cell migration (171) , and CXCR3 has been found to regulate synovial fibroblast invasion in rheumatoid arthritis (83) . In addition, fibrocytes, circulating progenitors of fibroblasts, express CXCR4 and migrate in response to CXCL12/ SDF-1␣ (124) . Therefore, the expression and function of CXC receptors in lung fibroblasts should be determined.
Chemokine Receptors as Mediators of Cross Talk between Lung Tissue and the Immune System
Chemokine receptors/chemokines in the lung contribute to inflammatory and immune responses as well as to the regulation of lung tissue cell functions, thus mediating the interplay between resident lung tissue cells and inflammatory and immune cells to maintain the airway homeostasis and normal lung function (46) . As shown in Fig. 2 , upon stimulation, resident structural lung cells release a number of chemokines that contribute to the recruitment of inflammatory and immune cells to the site of injury, and these inflammatory and immune cells may release secondary inflammatory mediators. These secondary mediators then may act on infiltrated inflammatory and immune cells and on lung tissue cells, further enhancing the immune response to the stimuli. Moreover, secreted chemokines interact with chemokine receptors expressed on structural lung cells and stimulate cell migration and proliferation, which contribute to tissue repair. The chemokine receptors/chemokines in the lung may thus function in a paracrine and autocrine manner, representing important molecular signals for communication between cells as well as for regulation of local inflammatory events (34) .
The chemokine receptors, therefore, have been proposed as attractive therapeutic targets in lung diseases, giving hope that selective receptor antagonism might allow us to control which cells are recruited and activated (140) . Indeed, murine models with deleted chemokine receptor genes as well as studies with neutralizing antibodies and chemokine receptor antagonists have already shown reduction of airway inflammation and disease-like phenotype. The "redundancy" in chemokine receptors as well as contradictory results from certain knockout mice and neutralizing antibody studies (128, 137) indicate the complexity of the lung-immune system. A concerted cellular and molecular interaction is critical for a dynamic, sustained, and regulated response toward the homeostasis (34) .
CONCLUSIONS AND PERSPECTIVES
Chemokine receptors and their ligands have been critically implicated in diseased lung. Traditionally confined to immune cells, chemokine receptors/chemokines have been found also in lung tissue cells, where they mediate a variety of functions. These findings thus attribute chemokine receptors and chemokines more significant roles than previously expected. Moreover, a novel group of atypical chemokine receptors, discovered recently, might also contribute to the physiological and pathophysiological processes in the lung. Therefore, further studies focused on the role of multiple chemokine receptor families are needed for better understanding of the cellular and molecular network in the lung and the development of efficient therapeutic strategies. 
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